Actively Recruiting
PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults
Led by Poznan University of Medical Sciences · Updated on 2026-03-16
120
Participants Needed
1
Research Sites
50 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will compare three different versions of the Pericapsular Nerve Group (PENG) block in adults aged 65 years and older who are undergoing surgery for hip conditions. The PENG block is a regional anesthesia technique that can reduce pain after surgery and decrease the need for strong opioid pain medications. All patients in the study will receive the PENG block with 20 mL of 0.2% ropivacaine, but they will be divided into three groups based on the additional medications used: Group 1: PENG block with ropivacaine plus 4 mg of dexamethasone given intravenously. Group 2: PENG block with ropivacaine plus 25 micrograms of dexmedetomidine given near the nerves and 4 mg of dexamethasone given intravenously. Group 3: PENG block with ropivacaine plus 25 micrograms of dexmedetomidine and 4 mg of dexamethasone given near the nerves. Both dexmedetomidine and dexamethasone are medications that may improve the strength and duration of nerve blocks. The main goal of this study is to determine which combination provides the best pain control after hip surgery, reduces the need for opioid medications, and improves patient comfort and recovery. We also aim to evaluate the safety and side-effects of each technique. We hypothesize that adding both dexmedetomidine and dexamethasone near the nerves will provide the longest and most effective pain relief when compared to intravenous administration alone. This trial may help identify the most effective PENG block formula for older adults undergoing hip surgery and could improve pain management, decrease complications related to opioids, and support faster recovery.
CONDITIONS
Official Title
PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 years or older
- Scheduled for elective or emergency hip surgery such as hip fracture fixation or hip arthroplasty
- ASA physical status I-III
- Ability to communicate pain intensity using the numeric rating scale
- Written informed consent given by patient or legal representative
- Planned use of PENG block as part of multimodal perioperative analgesia
You will not qualify if you...
- Refusal or inability to provide informed consent
- Allergy, intolerance, or contraindication to ropivacaine, dexamethasone, or dexmedetomidine
- Pre-existing neurological deficit or neuropathy of the affected limb
- Coagulopathy or current therapeutic anticoagulation contraindicating regional anesthesia
- Infection at or near the injection site
- Severe liver or kidney impairment
- History of chronic opioid use (daily use for more than 30 days before surgery)
- Cognitive impairment or delirium preventing reliable pain assessment
- Body mass index over 40 kg/m²
- Receiving another regional nerve block for hip surgery
- Pregnancy or breastfeeding
- Participation in another interventional clinical trial within 30 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Poznan University of Medical Sciences
Poznan, Poland, 62-701
Actively Recruiting
Research Team
M
Malgorzata Reysner, MD PhD
CONTACT
M
Mslgorzata Reysner, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here